ALX Oncology Holdings Inc. ALXO reported positive results from an ongoing phase I/II investigator-sponsored study of evorpacept, in combination with Roche’s RHHBY Rituxan (rituximab) and Bristol Myers...
Source LinkALX Oncology Holdings Inc. ALXO reported positive results from an ongoing phase I/II investigator-sponsored study of evorpacept, in combination with Roche’s RHHBY Rituxan (rituximab) and Bristol Myers...
Source Link
Comments